Gan & Lee's GLR1075 Injection Wins NMPA Approval for Clinical Trial in Cirrhotic Ascites Hypoalbuminemia
Gan & Lee Pharmaceuticals (603087) announced on September 18, 2026 that the company recently received a Drug Clinical Trial Approval Notice issued by the National Medical Products Administration, covering its investigational product GLR1075 Injection.
The announcement shows that the National Medical Products Administration has agreed to allow GLR1075 Injection to conduct a clinical trial in hypoalbuminemia associated with cirrhotic ascites.
Why this event matters
The event has a measured impact on 1 industry. The strongest current signal is positive for Pharmaceuticals, with intensity 35/100 and 70% confidence over a medium term horizon.
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.